Literature DB >> 16890665

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

G Martorana1, R Schiavina, B Corti, M Farsad, E Salizzoni, E Brunocilla, A Bertaccini, F Manferrari, P Castellucci, S Fanti, R Canini, W F Grigioni, A D'Errico Grigioni.   

Abstract

PURPOSE: (11)C-choline positron emission tomography is an innovative imaging technique for prostate cancer. We assessed the sensitivity of positron emission tomography used together with computerized tomography for intraprostatic localization of primary prostate cancer on a nodule-by-nodule basis, and compared its performance with 12-core transrectal biopsy.
MATERIALS AND METHODS: In 43 patients with known prostate cancer who had received positron emission tomography/computerized tomography before initial biopsy, we assessed sensitivity of positron emission tomography/computerized tomography for localization of nodules 5 mm or greater (those theoretically large enough for visualization) using radical prostatectomy histopathology as the reference standard. Comparison with transrectal ultrasound guided biopsy was based on sextant assessment of all cancer foci following sextant-by-sextant matching and reconstruction. Sensitivity/specificity of positron emission tomography/computerized tomography and magnetic resonance imaging for prediction of extraprostatic extension was also assessed.
RESULTS: Positron emission tomography/computerized tomography showed 83% sensitivity for localization of nodules 5 mm or greater. At logistic regression analysis only nodule size appeared to influence sensitivity. At sextant assessment positron emission tomography/computerized tomography had slightly better sensitivity than transrectal ultrasound guided biopsy (66% vs 61%, p = 0.434) but was less specific (84% vs 97%, p = 0.008). For assessment of extraprostatic extension, sensitivity of PET/CT was low in comparison with magnetic resonance imaging (22% vs 63%, p <0.001).
CONCLUSIONS: Positron emission tomography/computerized tomography has good sensitivity for intraprostatic localization of primary prostate cancer nodules 5 mm or greater. Positron emission tomography/computerized tomography and transrectal ultrasound guided biopsy show similar sensitivity for localization of any cancer focus. Positron emission tomography/computerized tomography does not seem to have any role in extraprostatic extension detection. Studies of diagnostic accuracy (as opposed to tumor localization) are needed in patients with suspected prostate cancer to see whether positron emission tomography/computerized tomography could have a role in not selected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890665     DOI: 10.1016/j.juro.2006.04.015

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  34 in total

1.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

2.  [Imaging diagnostics of the prostate].

Authors:  D J Dinter; A M Weidner; F Wenz; A E Pelzer; M S Michel; S O Schoenberg
Journal:  Urologe A       Date:  2010-08       Impact factor: 0.639

Review 3.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 4.  [Choline PET/CT in the diagnosis of primary and recurrent prostate cancer. Are there evidence-based indications?].

Authors:  P J Olbert; J Heinis; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

5.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

Review 6.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

Review 7.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

8.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

Review 9.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

10.  The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)--a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.

Authors:  Berardino De Bari; Filippo Alongi; Pierfrancesco Franco; Patrizia Ciammella; Tarik Chekrine; Lorenzo Livi; Barbara A Jereczek-Fossa; Andrea Riccardo Filippi
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.